Investor Information

News

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

View News

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View News

More Information

Share Price

NASDAQ: SMMT

19.60 USD

20-Mar-2025 13:00 UTC-4

More Information

SEC Filings

Current report filing

View News

Annual report pursuant to section 13 and 15(d)

View News

More Information

Email Alerts